Expect BREAST CANCER prediction MISDIAGNOSES to INCREASE with FDA-approved AI “determinations” forthcoming for scam-o-gram mammograms
By sdwells // 2025-06-09
Copy
 
Mammograms have been nicknamed “scam-o-grams” by the natural health community for decades for several good reasons. They cause serious health issues, including breast cancer. The breasts are smashed down by a machine, causing severe inflammation. Then they are prodded and poked. The woman undergoes extreme stress, and the readings are often misinterpreted due to “gray spots” that could be almost anything other than a cancer tumor. Then there’s the radiation factor. Now the Cancer Industrial Complex (CIC) wants to start using AI, artificial intelligence, to make these life-threatening decisions, further complicating the entire process of scam-o-grams, which often end in unnecessary surgery, medical errors, and misdiagnosis, including double mastectomy.

AI-powered mammogram analysis could revolutionize breast cancer risk prediction or add to the chaos of misdiagnosis and unnecessary surgeries

For decades, mammograms have been the gold standard for detecting breast cancer early—but what if they could also predict a woman’s risk of developing the disease before it appears? A groundbreaking AI-powered platform, Clairity Breast, has received FDA authorization to do just that. Developed with support from the Breast Cancer Research Foundation (BCRF), the tool analyzes subtle patterns in standard mammograms to estimate a woman’s five-year breast cancer risk, potentially transforming early detection into proactive prevention. Unlike traditional risk models that rely on age, family history, or genetic testing, Clairity Breast uses artificial intelligence to detect imaging patterns invisible to the human eye. In a study of over 30,000 mammograms, the platform identified surprising risk levels among younger women: 37% of women in their 40s were at intermediate risk, while 16% were high-risk—levels comparable to older women typically prioritized in screening guidelines. Dr. Larry Norton, BCRF’s founding scientific director, called the FDA authorization a “turning point,” adding, “Now, we can ensure more women get the right care at the right time.” Current risk models often miss women without a family history—85% of breast cancer patients—and have historically underrepresented diverse racial and ethnic groups. Clairity Breast aims to close these gaps by requiring only a standard mammogram and ensuring proportional representation in its AI training data. “A deeply important aspect of Clairity Breast is that it was developed with an intentional focus to reduce disparities,” said BCRF Chief Scientific Officer Dr. Dorraya El-Ashry. Clairity Breast’s risk scores could prompt earlier interventions, such as MRIs, lifestyle changes, or preventive medications, while sparing low-risk women unnecessary tests. The platform is set to launch commercially in late 2025, with efforts underway to secure insurance coverage. As AI reshapes healthcare, Clairity Breast represents a leap forward in personalized, equitable cancer prevention. “For more than 60 years, mammograms have saved lives by detecting early-stage cancers,” said Dr. Connie Lehman, Clairity’s founder. “Now, AI can uncover hidden clues to predict future risk.” With this innovation, the future of breast cancer care may shift from reactive treatment to proactive prevention—a change that could save countless lives,” or ruin them. Tune your internet dial to NaturalMedicine.news for more tips on how to use natural remedies for preventative medicine and for healing, instead of succumbing to Big Pharma products, like mammograms, radiation and chemotherapy, that cause, spread, and exacerbate disease and disorder. Sources for this article include: NaturalNews.com BCRF.org    
Copy